A detailed history of Cullen/Frost Bankers, Inc. transactions in Organon & Co. stock. As of the latest transaction made, Cullen/Frost Bankers, Inc. holds 216 shares of OGN stock, worth $3,231. This represents 0.0% of its overall portfolio holdings.

Number of Shares
216
Previous 384 43.75%
Holding current value
$3,231
Previous $7,000 42.86%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 06, 2024

SELL
$18.65 - $23.03 $3,133 - $3,869
-168 Reduced 43.75%
216 $4,000
Q2 2024

Aug 05, 2024

BUY
$17.45 - $21.96 $1,936 - $2,437
111 Added 40.66%
384 $7,000
Q1 2024

May 10, 2024

SELL
$13.78 - $18.8 $771 - $1,052
-56 Reduced 17.02%
273 $5,000
Q4 2023

Feb 06, 2024

SELL
$10.95 - $17.32 $16,184 - $25,598
-1,478 Reduced 81.79%
329 $4,000
Q3 2023

Nov 02, 2023

BUY
$16.59 - $23.77 $116 - $166
7 Added 0.39%
1,807 $31,000
Q2 2023

Aug 04, 2023

SELL
$19.27 - $24.63 $982 - $1,256
-51 Reduced 2.76%
1,800 $37,000
Q1 2023

May 05, 2023

SELL
$21.42 - $32.08 $835 - $1,251
-39 Reduced 2.06%
1,851 $43,000
Q4 2022

Feb 13, 2023

SELL
$23.31 - $28.61 $14,219 - $17,452
-610 Reduced 24.4%
1,890 $52,000
Q3 2022

Nov 07, 2022

SELL
$23.4 - $34.25 $30,185 - $44,182
-1,290 Reduced 34.04%
2,500 $59,000
Q2 2022

Aug 05, 2022

SELL
$31.66 - $38.9 $1,393 - $1,711
-44 Reduced 1.15%
3,790 $128,000
Q1 2022

May 09, 2022

BUY
$30.45 - $39.36 $3,410 - $4,408
112 Added 3.01%
3,834 $134,000
Q4 2021

Feb 07, 2022

SELL
$28.67 - $37.13 $67,145 - $86,958
-2,342 Reduced 38.62%
3,722 $113,000
Q3 2021

Nov 04, 2021

SELL
$28.63 - $35.64 $65,305 - $81,294
-2,281 Reduced 27.33%
6,064 $199,000
Q2 2021

Aug 05, 2021

BUY
$28.45 - $38.0 $237,415 - $317,110
8,345 New
8,345 $253,000

Others Institutions Holding OGN

About Organon & Co.


  • Ticker OGN
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 254,330,000
  • Market Cap $3.8B
  • Description
  • Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio...
More about OGN
Track This Portfolio

Track Cullen/Frost Bankers, Inc. Portfolio

Follow Cullen/Frost Bankers, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cullen/Frost Bankers, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Cullen/Frost Bankers, Inc. with notifications on news.